contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


modus-therapeutics-receives-approval-to-initiate-a-phase-iia-clinical-trial-for-chronic-kidney-disease-ckd

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Modus Therapeutics operates in the biotechnology industry. The product portfolio is broad and includes, for example, sevuparin. The company's focus is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. In addition to the main business, service and associated ancillary services are also offered. The activities with associated research are conducted in Sweden. 

Modus Therapeutics Holding

STOCKHOLM, SWEDEN – November 18, 2024: Modus Therapeutics Holding AB ("Modus") announces that it has received approval from the relevant authorities in Italy for its planned Phase IIa clinical...

<div class="mfn-preamble"><p><strong>STOCKHOLM, SWEDEN – November 18, 2024: Modus Therapeutics Holding AB ("Modus") announces that it has received approval from the relevant authorities in Italy for its planned Phase IIa clinical trial with sevuparin.</strong></p></div><div class="mfn-body"><p>As previously communicated, the planned Phase IIa study will be conducted in two parts. Part 1 aims to establish dosage levels and safety of sevuparin through single doses in 25-30 patients with varying degrees of kidney failure. Part 1 will also include a small reference group of healthy volunteers and may also provide an opportunity to assess early effects on hepcidin in a relevant patient population.</p><p>Part 2, the so-called "proof of concept" segment, will evaluate the effects of repeated dosing of sevuparin based on the dose levels established in Part I, focusing on endpoints related to anemia, hepcidin, kidney status, and relevant biomarkers in patients with more severe chronic kidney disease and anemia. It is expected to recruit 25-30 patients, bringing the total study enrollment to 50-60 patients. The approval is in line with Modus’ target to execute Part I of the study during the first half of 2025.</p></div><div class="mfn-footer mfn-contacts mfn-4a56f54c1f70"><p><strong class="mfn-heading-1">For more information on Modus Therapeutics, please contact:</strong><br>John Öhd, CEO, Modus Therapeutics<br>Phone: +46 (0) 70 766 80 97<br>Email: <a rel="noopener" href="mailto:john.ohd@modustx.com">john.ohd@modustx.com</a></p></div><div class="mfn-footer mfn-fba5366acfa1"><p><strong class="mfn-heading-1">Certified Adviser</strong><br>Svensk Kapitalmarknadsgranskning AB<br>Website: <a rel="noopener" href="http://www.skmg.se">www.skmg.se</a></p></div><div class="mfn-footer mfn-about mfn-0225634101f8"><p><strong class="mfn-heading-1">About Modus Therapeutics and sevuparin</strong><br>Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at&nbsp;<a rel="noopener" href="http://www.modustx.com/">www.modustx.com</a>.</p><p>Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/fad2fefc-a167-4e34-958b-f43ee5010ee0/modus-therapeutics-receives-approval-to-initiate-a-phase-iia-clinical-trial-for-chronic-kidney-disease-ckd.pdf" class="mfn-generated mfn-primary">Modus Therapeutics Receives Approval to Initiate a Phase IIa Clinical Trial for Chronic Kidney Disease (CKD)</a></p></div>

Modus Therapeutics Receives Approval to Initiate a Phase IIa Clinical Trial for Chronic Kidney Disease (CKD)